Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 CAR iT cell therapy - Fate Therapeutics

Next Previous
Search
Drug Profile

Anti-CD19 CAR iT cell therapy - Fate Therapeutics

Alternative Names: Anti-CD19 NxG CAR iT cell therapy; multiplexed-engineered, next-generation (NxG) CAR T cell therapy; Next-Generation Off-the-Shelf CAR T-Cell Therapy

Latest Information Update: 27 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fate Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Induced pluripotent stem cell therapies; Pluripotent stem cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological disorders

Most Recent Events

  • 06 Feb 2025 Fate Therapeutics has patent pending for induced pluripotent stem cell (iPSC) technology (Fate Therapeutics website, February 2025)
  • 06 Feb 2025 Fate Therapeutics has patent protection for induced pluripotent stem cell (iPSC) technology (Fate Therapeutics website, February 2025)
  • 07 Dec 2024 Preclinical trials in Haematological disorders in USA (Parenteral) before December 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top